SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: Identification of CDA SNP C-451T as an independent prognostic parameter for survival

Leukemia

Volumn 23, Issue 10, 2009, Pages 1929-1932

  Mahlknecht, U ^a,b   Dransfeld, C L ^a,b   Bulut, N ^b   Kramer, M ^c   Thiede, C ^c   Ehninger, G ^c   Schaich, M ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; CD34 ANTIBODY; CYTARABINE; CYTIDINE DEAMINASE; DAUNORUBICIN; ETOPOSIDE; GENOMIC DNA; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BRAIN TOXICITY; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 8; CLINICAL TRIAL; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EYE TOXICITY; GASTROINTESTINAL TOXICITY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KARYOTYPE; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 70350120572     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.113     Document Type: Article

References (12)

1. Stam RW, den Boer ML, Meijerink JP, Ebus ME, Peters GJ, Noordhuis P et al. Differential mRNA expression of Ara-Cmetabolizing enzymes explains Ara-C sensitivity in MLL generearranged infant acute lymphoblastic leukemia. Blood 2003; 101: 1270-1276.
2. Coleman CN, Stoller RG, Drake JC, Chabner BA. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood 1975; 46: 791-803.
3. Schaich M, Ritter M, Illmer T, Lisske P, Thiede C, Schakel U et al Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol 2001; 112: 300-307.
4. Gramatzki M, Ludwig WD, Burger R, Moos P, Rohwer P, Grunert C et al Antibodies TC-12 ('unique') and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol 1998; 26: 1209-1214.
5. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
6. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M et al Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011-4020.
7. Mohr B, Bornhauser M, Thiede C, Schakel U, Schaich M, Illmer T et al Comparison of spectral karyotyping and conventional cytogenetics in 39 patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2000; 14: 1031-1038.
8. Smigielski EM, Sirotkin K, Ward M, Sherry ST. dbSNP: A database of single nucleotide polymorphisms. Nucleic Acids Res 2000; 28: 352-355.
9. The International HapMap Project. Nature 2003; 426: 789-796.
10. De La Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA. New generation pharmacogenomic tools: A SNP linkage disequilibrium Map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. Biotechniques 2002, Suppl: 48-50, 52, 54.
11. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: The impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32-42.
12. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 2006; 119: 276-283.